Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group AG    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
574.4(c) 577.8(c) 556(c) 553.2(c) 555.2(c) Last
178 762 201 449 250 476 189 787 270 151 Volume
-0.10% +0.59% -3.77% -0.50% +0.36% Change
More quotes
Financials
Sales 2020 6 166 M 6 725 M 6 725 M
Net income 2020 858 M 936 M 936 M
Net Debt 2020 2 825 M 3 081 M 3 081 M
P/E ratio 2020 47,1x
Yield 2020 0,53%
Sales 2021 6 633 M 7 235 M 7 235 M
Net income 2021 986 M 1 075 M 1 075 M
Net Debt 2021 2 428 M 2 648 M 2 648 M
P/E ratio 2021 40,2x
Yield 2021 0,58%
Capitalization 41 097 M 44 852 M 44 824 M
EV / Sales 2020 7,12x
EV / Sales 2021 6,56x
Nbr of Employees 15 913
Free-Float 99,6%
More Financials
Company
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, nutritional ingredients, etc. In addition, the group offers dosage solutions for... 
More about the company
Notations Surperformance© of Lonza Group AG
Trading Rating : Investor Rating :
More Ratings
All news about LONZA GROUP AG
11:58aLonza to make COVID-19 antibody combination for AstraZeneca
RE
02:11aLONZA : to make COVID-19 antibody combination for AstraZeneca
RE
02:05aLONZA : Announces Agreement to Manufacture AstraZeneca's COVID-19 Long-Acting An..
PU
10/22LONZA : Expands Its Capsule Manufacturing Capacity
PU
10/16LONZA : Investor Update Details Business Structure, Divisional Dynamics, New Ext..
AQ
10/15LONZA : Investor Update Presentation
PU
10/15GLOBAL MARKETS LIVE : Tiffany & Co, Morgan Stanley, Roche...
10/15LONZA : Strengthens Focus on Pharma and Biotech --Update
DJ
10/15LONZA : Issues 2023 Guidance
DJ
10/15LONZA : Investor Update Details Business Structure, Divisional Dynamics, New Ext..
PU
10/02LONZA : Launches the PyroCell Monocyte Activation Test System for Reliable and S..
AQ
10/01LONZA : Launches the PyroCell Monocyte Activation Test System for Reliable and S..
PU
09/30LONZA LAUNCHES ITS FIRST PROBIOTIC I : TWK10 Brand
PU
09/30LONZA LAUNCHES SALE OF $3.5 BILLION : sources
RE
09/30Lonza confident of 2020 target for Moderna COVID-19 vaccine supply
RE
More news
News in other languages on LONZA GROUP AG
03:21aSTOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
02:31aLonza stellt für AstraZeneca möglichen Covid-19-Wirkstoff her
02:28aASTRAZENECA : Lonza erhält Zuschlag für Produktion von Covid-Medikament
02:14aLonza va produire les anticorps d'Astrazeneca contre le Covid-19
10/27Peur sur la reprise
More news
Stock Trading Strategies
LONZA GROUP AG - 10/02
The stock is approaching a major resistance level
BUY
More Stock Trading Analysis
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 570,71 CHF
Last Close Price 553,20 CHF
Spread / Highest target 27,6%
Spread / Average Target 3,16%
Spread / Lowest Target -41,1%
EPS Revisions
Managers
NameTitle
Albert M. Baehny Chairman & Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Juergen B. Steinemann Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG56.63%44 852
SEAGEN INC.68.34%33 467
CELLTRION, INC.33.15%29 849
IQVIA HOLDINGS INC.0.09%29 650
MODERNA, INC.264.42%28 126
IMMUNOMEDICS, INC.315.22%20 324